2 results
Approved WMOCompleted
The primary objective is to assess the proportion of patients in each treatment arm with a satisfactory clinical response as defined by a composite primary endpoint at Week 24.The secondary objective is to demonstrate safety and clinical effect at…
Approved WMORecruiting
Study Objectives:The purpose of this Phase 2 study is to evaluate the safety, efficacy, pharmacokinetics (PK),pharmacodynamics (PD), and immunogenicity of narsoplimab in paediatric-aged patients withthrombotic microangiopathies (TMA) following…